Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

30.77 +1.01 (+3.39%)
Official Closing Price Updated: 7:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 35,629,780
Open 30.15
Bid (Size) 30.70 (4)
Ask (Size) 30.71 (3)
Prev. Close 29.76
Today's Range 30.01 - 30.88
52wk Range 25.20 - 37.34
Shares Outstanding 5,606,688,356
Dividend Yield 5.33%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
These stocks arguably deserve more respect from investors. 
Via The Motley Fool

Performance

YTD
+3.50%
+3.50%
1 Month
+9.93%
+9.93%
3 Month
+21.81%
+21.81%
6 Month
+12.01%
+12.01%
1 Year
-17.31%
-17.31%

More News

Read More
Freeport-McMoRan, Pfizer, Danaher And An Industrial Stock: CNBC's 'Final Trades'
Via Benzinga
Get Your Money Out of These 3 Dividend Stocks by 2025
Via InvestorPlace
What's Going On With Pfizer Stock Thursday?
Via Benzinga
Pfizer's Options: A Look at What the Big Money is Thinking
Via Benzinga
Check Out What Whales Are Doing With PFE
Via Benzinga
European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
From Pfizer Inc.
Via Business Wire
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
Via FinancialNewsMedia
Exposures Product Safety
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
7 Dividend Stocks to Hold On Tight to for the Next Decade
Via InvestorPlace
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
Via The Motley Fool
Beware, Wegovy -- Pfizer Is Working on a Competitor
Via The Motley Fool
Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?
Via InvestorPlace
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
Via Benzinga
This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer
Via The Motley Fool
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Via Benzinga
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
From Pfizer Inc.
Via Business Wire
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
Via Benzinga
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Via Benzinga
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
Via The Motley Fool
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
Via The Motley Fool
Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.